Login
$INBX
$77.66 -$5.64 (6.77%) Live

$INBX SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 S-3ASR
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition

San Diego, CA, November 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

28 Oct 2026 SCHEDULE 13G/A
14 Oct 2026 Form 4: Lappe Mark, Director

Bought 10,040 shares ($849K)

28 Sep 2026 Form 4: Lappe Mark, Director

Bought 5,500 shares ($545K) · Bought 4,500 shares ($453K)

28 Sep 2026 8-K: Regulation FD Disclosure

INHIBRX Investor Presentation Innovation Driven Outcomes Focused •

23 Sep 2026 Form 4: Kayyem Jon Faiz, Director

Bought 5,000 shares ($500K)

18 Sep 2026 Form 4/A: Forsyth Douglas, Director

Granted 10,000 Stock Option (right to buy)

18 Sep 2026 Form 4/A: Vuori Kristiina Md, Director

Granted 10,000 Stock Option (right to buy)

18 Sep 2026 Form 4/A: Manhard Kimberly, Director

Granted 10,000 Stock Option (right to buy)

18 Sep 2026 Form 4/A: Kayyem Jon Faiz, Director

Granted 10,000 Stock Option (right to buy)

17 Sep 2026 Form 4: Kayyem Jon Faiz, Director

Bought 5,000 shares ($500K)

15 Sep 2026 Form 4: Manhard Kimberly, Director

Sold 500 shares ($55.9K) · Sold 500 shares ($55.1K) · Sold 500 shares ($52.5K)

15 Sep 2026 144
14 Sep 2026 144
11 Sep 2026 144
10 Sep 2026 Form 4: Manhard Kimberly, Director

Sold 500 shares ($57.6K) · Sold 500 shares ($57.9K)

09 Sep 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support